Successful therapy with mycophenolic acid in a membranous glomerulonephritis due to Kimura disease

• Published in: Clinical nephrology Vol. 88; no. 10; pp. 221 - 225
• Main Authors: Gaillard, Julien, Rotman, Samuel, Girardet, Christophe, Spertini, François
• Format: Journal Article
• Language: English
• Published: Germany Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG 01.10.2017
• Subjects: Acids; Angiolymphoid Hyperplasia with Eosinophilia - complications; Biopsy; Blood vessels; Creatinine; Edema; Exocrine glands; Female; Glomerulonephritis, Membranous - drug therapy; Glomerulonephritis, Membranous - etiology; Humans; Hyperplasia; Immunosuppressive Agents - therapeutic use; Lymphatic system; Microscopy; Middle Aged; Mycophenolic Acid - therapeutic use; Proteins; Remission (Medicine); Steroids; Treatment Outcome; Urine
• ISSN: 0301-0430
• DOI: 10.5414/CN109086

Kimura disease (KD) is a rare inflammatory soft tissue disorder of unknown origin most frequent in Asians, the prevalence of which is growing in Western countries. Painless papules and/or nodules with a predilection for the head and the neck region, lymphadenopathies, parotid gland involvement, eosinophilia, and raised IgE levels are parts of its presentation. Renal involvement with various forms of glomerulonephritis, including membranous nephropathy (MN), can occur and is generally associated with a proteinuria that encompasses nephrotic syndrome. Corticosteroids are the mainstay of treatment of KD-associated glomerulonephritis, but steroids withdrawal is often followed by relapsing nephrotic syndrome. Various immunosuppressive agents have been tested to prolong the remission of KD-associated nephrotic syndrome while tapering steroids, but they are only partly effective or associated with significant complications. To the best of our knowledge, we describe here the first case of KD-related membranous glomerulonephritis with a favorable evolution and a sustained remission of 4 years under prolonged therapy with mycophenolic acid (MPA). MPA and its active metabolite, mycophenolate mofetil (MMF), treatments as supportive therapies to corticosteroids and ACE inhibitors should be further investigated in KD-related membranous nephropathies.
.